|
Oct 2
|
Processa Pharmaceuticals Announces First Patient Dosed in Phase 2 Clinical Trial of NGC-Cap in Metastatic Breast Cancer
|
|
Jul 30
|
Processa Pharmaceuticals Announces FDA Clearance of IND Application for a Phase 2 Clinical Trial of NGC-Cap in Breast Cancer
|
|
Jan 2
|
Processa Pharmaceuticals to Present at the Biotech Showcase 2024
|
|
Nov 30
|
Processa Pharmaceuticals to Present at the MedInvest Oncology Investor Conference
|
|
Nov 29
|
Processa Pharmaceuticals Issues Letter to Shareholders Highlighting Corporate Strategy, Drug Pipeline, and Outlook
|